PTPRG and rhabdomyosarcoma: Moreover, PTPRG could also modulate the activity of FGFR4 in rhabdomyosarcoma, indeed using siRNA against PTPRG in FGF-treated RH30 cell line increases phosphorylation of the receptor FGFR4 and downstream molecule such as PLCG1 (Phospholipase C-gamma 1) compared to the scramble control (Kostas et al., 2018).